Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in TNBC
NCT06175390Phase 2Active, not recruiting
- Sponsor
- Institut Curie
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of tiragolumab, atezolizumab in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Started Mar 2024; status: active, not recruiting.
02
Drugs
tiragolumabatezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06175390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175390.